Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab

Durvalumab is a therapeutic monoclonal antibody that blocks the checkpoint inhibitor, programmed death ligand 1 (PD-L1), resulting in T-cell activation and an antitumor response. Durvalumab is approved for patients with unresectable stage III non-small-cell lung cancer (NSCLC) which has not progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ashish, Tun, Aung, Ticona, Katy, Baqui, Aam, Guevara, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732593/
https://www.ncbi.nlm.nih.gov/pubmed/31534809
http://dx.doi.org/10.1155/2019/2178925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732593/
https://www.ncbi.nlm.nih.gov/pubmed/31534809
http://dx.doi.org/10.1155/2019/2178925

Ejemplares similares